Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8)

Recruiting

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(4 sites)

China

Beijing Chest Hospital, Beijing, Beijing Municipality

Shanghai Chest Hospital, Shanghai, Shanghai Municipality

Zhejiang Cancer Hospital, Hangzhou, Zhejiang

Zhejiang Taizhou Hospital, Taizhou, Zhejiang